CCL3 News and Research

RSS

Comparison of blood plasma protein expression in mild, moderate, and severe COVID-19 identifies novel disease severity biomarkers

Researchers evaluated blood plasma proteins to identify new targets for COVID-19 treatment approaches and prevent complications associated with severe illness.

5 Dec 2022

What is the association between natural killer cell dysfunction and COVID-19 disease severity?

Researchers assessed the association between natural killer cell dysfunction and COVID-19 disease severity.

20 Jul 2022

Role of SARS-CoV-2 S1 subunit in severe COVID-19

A new study aimed to determine whether portions of the SARS-CoV-2 spike protein are capable of activating innate immune cells like Gal-3.

30 Mar 2022

Dual therapeutic potential of zapnometinib against COVID-19

Researchers assessed the impact of the drug zapnometinib on human immune response against coronavirus disease 2019.

2 Mar 2022

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

In a recent study published in the journal ACS Applied Bio Materials, researchers demonstrated the inhibitory potential of curcumin-encapsulated polysaccharide nanoparticles (CUR−PS-NPs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (CoV2-SP)-stimulated cytokine storm in lung and liver epithelial cells.

8 Feb 2022

Researchers investigate SARS-CoV-2 specific inflammatory response

New research can confirm that while some of the response from monocytes to SARS-CoV-2 is generic to virus infection, most of it SARS-CoV-2 specific, especially proinflammatory responses.

7 Jan 2022

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Researchers look to gain an understanding of the mechanism of action of budesonide in improving the prognosis of patients with SARS-CoV-2 infection.

1 Nov 2021

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

A team of scientists from the USA and France has recently unveiled the mechanism of immune dysregulation in coronavirus disease 2019 (COVID-19) patients by analyzing the early-stage interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected epithelial cells and immune cells. The study is currently available on the bioRxiv* preprint server.

30 Sep 2021

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Recently, a new study published on the pre-print server bioRxiv* examined the effect that maternal asymptomatic COVID-19 had on decidual and peripheral immune cells during the later stage of pregnancy.

30 Aug 2021

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

A new study discusses how both different responses to the infection itself and to COVID-19 vaccines are likely the result of genetic differences.

25 Jul 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

CD39+ monocyte count higher in pregnant than non-pregnant COVID-19 patients

A new study published on the bioRxiv* server describes the changes in the representation of a subset of activated monocytes in this group of patients.

23 Jun 2021

The role of natural killer cells in fight against viral infections including SARS-CoV-2

In an effort to further understand the role of NK cells in combatting COVID-19, a group of researchers explored NK cells in acute viral infections, citing flavivirus and influenza virus infections as examples.

17 Jun 2021

Pathogenic airway neutrophilia drives ARDS in Black patients with severe COVID-19 in case study

Researchers from the US used a systems immunology approach where they combined high-dimensional flow cytometry and multi-omics single-cell sequencing analyses of immune profiles taken from the airways and matching blood samples of Black/AA patients.

9 Jun 2021

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

A new study shows that the immunological features of severe COVID-19 are already present in healthy older adults and in men, before they are infected, indicating a possible explanation for this differential susceptibility towards the virus.

6 May 2021

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.

21 Apr 2021

Vaccine-induced 2C08 antibody protects against SARS-CoV-2 variants

A new preprint study posted to the bioRxiv* server led by Ali H. Ellebedy from the Washington University School of Medicine found that the monoclonal antibody 2C08 produced by the Pfizer vaccine could help neutralize COVID-19 variants.

29 Mar 2021

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

In a recent bioRxiv preprint research paper, Botond Z. Igyártó and colleagues from Thomas Jefferson University demonstrated the inflammatory nature of the lipid nanoparticles (LNPs).

15 Mar 2021

NK and T cell subsets show distinctive lung-homing receptor profiles in COVID-19 patients

A new study reveals in detail the changes that occur in peripheral blood natural killer (NK) and T cells in COVID-19.

18 Jan 2021

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020